Table 4.
BTA treatment and clinical characteristics by phenotype among the 524 patients with confirmed bone metastases
| HR+ HER2+ | HR+ HER2− | HR− HER2+ | Triple negative | |
|---|---|---|---|---|
| N (phenotype available) | 63 | 320 | 23 | 67 |
| BTA treated (ever) | 76% | 81% | 83% | 55% |
| Median follow-up (months) | 22.6 | 23.6 | 17.5 | 9.3 |
| Percent of group | ||||
| Visceral metastases | 73% | 67% | 78% | 78% |
| 3+ metastatic sites | 49% | 36% | 43% | 57% |
| Pain at bone metastasis diagnosis | 48% | 47% | 48% | 57% |
| ECOG 2+ | 2% | 3% | 4% | 3% |
Notes: HR (hormone receptor) status refers to estrogen receptor (ER) and progesterone receptor (PR) status; triple negative refers to ER, PR, and HER2 receptor-negative status.
Abbreviations: BTA, bone-targeting agent; HER2, human epidermal growth factor receptor 2; ECOG, Eastern Cooperative Oncology Group.